Last reviewed · How we verify
CLS001 Topical Gel
At a glance
| Generic name | CLS001 Topical Gel |
|---|---|
| Sponsor | Maruho Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Study to Evaluate the Safety and Efficacy of a Once-Daily CLS001 Topical Gel Versus Vehicle (PHASE3)
- Study to Evaluate the Safety and Efficacy of a Once-Daily CLS001 Topical Gel Versus Vehicle (PHASE3)
- Pharmacodynamics, Safety/Tolerability and Efficacy of Topical Omiganan in Patients With uVIN (PHASE2)
- Pharmacodynamics, Safety and Efficacy of Topical Omiganan in Patients With External Genital Warts (PHASE2)
- A Study to Evaluate the Safety and Efficacy of Omiganan (CLS001) Topical Gel Versus Vehicle in Female Subjects With Moderate to Severe Acne Vulgaris (PHASE2)
- Pharmacodynamics of Omiganan (CLS001) in Patients With Atopic Dermatitis (PHASE2)
- Safety and Efficacy Study of CLS001Topical Gel Compared to Vehicle in Subjects With Inflammatory Acne Vulgaris (PHASE2)
- A Twelve Week Safety and Efficacy Study in Rosacea (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CLS001 Topical Gel CI brief — competitive landscape report
- CLS001 Topical Gel updates RSS · CI watch RSS
- Maruho Co., Ltd. portfolio CI